Keywords: novartis, sublicenses, hrt, patches, r-pr, acquired, marketing

Novartis sublicenses HRT patches from R-PR

Article | 11 October 1999

Novartis has acquired marketing rights in Europe and certain otherworld markets for Estalis (transdermal estradiol/ norethisterone) and Menorest (transdermal 17-beta-estradiol), ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novartis

Go to company listing

Related Drugs

Estrace

Estradiol

Evamist

Testosterone

transdermal

Go to drug listing